Jaw Lesion and Discomfort

Levin, Liran; Luder, Liat

doi:10.1001/jama.2013.282405

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18][19][20][21][22][23][24][25][26][27][28][29][55][56][57][58][59][60][61][62] As a consequence, targeted agents with antiangiogenic properties are now ascribed as a possible risk factor for ONJ in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature

Fusco

Porta

Saia

et al. 2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature

Fusco

Porta

Saia

et al. 2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…Besides one-third of the patients could be painless, and asymptomatic. [11,12] Important risk factors for the development of osteonecrosis caused by biphosphonates include brand of the drug, route, dose, and duration of the drug therapy.…”

Section: Discussionmentioning

confidence: 99%

“…While incidence of osteonecrosis was observedly rised to 21% in combined use of both drugs. [12,18,19] The most prevalent primary focus in breast, lung, and mandibular tumors was detected to be mandible, however mandible was the primary focus in only 9.6% of the cases with prostate cancer. [18] As factors inducing mandibular, and maxillary osteonecrosis related to biphosphonates, incessant movements of chewing, various microbiological agents, fragile mucosa 2 mm-thick which can be easily peeled away from the periosteum have been asserted.…”

Section: Submandibularmentioning

confidence: 99%

Mandibular osteonecrosis due to bisphosphonate use

Salvarci

Altınay

2015

Turkish Journal of Urology

View full text Add to dashboard Cite

Due to their efficient osteoclastic inhibitor effect in bone metabolism and antiangiogenic activity, bisphosphonates are widely used in many cancer diseases particularly in prostate cancers with bone metastasis, lung cancer, breast cancer and multiple myeloma, as well as in systemic diseases such as osteoporosis, osteopenia, Paget disease and osteogenesis imperfect for the last 13 years. Prostate cancer is a common cancer in males and it is the leading cause of bone metastasis. Mandibular metastasis is rarely encountered during the course of prostate cancer. Mandibular osteonecrosis as well has begun to be observed along with the availability of more efficient and stronger formulations developed following the use of bisphosphonates. Zolendronic acid, which has been used also by our patient, has widely come into practice as a 3 rd generation bisphosphonate. Because of prostate cancer and widespread bone metastases, our patient has been receiving zolendronic acid with maximum androgen blockage for 4 years. Tomography of the patient, who has undergone intensive treatment because of submandibular abscess, demonstrated extensive osteonecrosis in the fovea sublingual region of the mandible corpus. In large series, although, mandibular osteonecrosis was widely seen due to bisphosphonate use for the metastases of lung and breast cancers, this rate was between 9.6% and 11% for prostate cancer within the series. Although our patient had no mandibular metastasis before, mandibular necrosis was observed due to long-term bisphosphonate use. We are going to present our patient who had this rare complication with his clinical picture.

show abstract

Zoledronic acid

2014

Reactions Weekly

View full text Add to dashboard Cite

Jaw Lesion and Discomfort

Cited by 4 publications

References 10 publications

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature

Mandibular osteonecrosis due to bisphosphonate use

Zoledronic acid

Contact Info

Product

Resources

About